HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) Will Pay A CN¥0.144 Dividend In Two Days
HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) Will Pay A CN¥0.144 Dividend In Two Days
HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) stock is about to trade ex-dividend in two days. The ex-dividend date is one business day before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Therefore, if you purchase HPGC Renmintongtai Pharmaceutical's shares on or after the 25th of July, you won't be eligible to receive the dividend, when it is paid on the 25th of July.
HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829)的股票將於兩天後交易分紅派息。除淨日是記錄日前的一個營業日,即股東出現在公司賬簿中以享有股息支付的截止日期。除息日很重要,因爲股票上的任何交易都必須在記錄日之前結算才有資格獲得分紅。所以,如果你在7月25日之後購買HPGC人民同泰藥品的股份,你將無法獲得分紅,該分紅將於7月25日支付。
The company's next dividend payment will be CN¥0.144 per share. Last year, in total, the company distributed CN¥0.14 to shareholders. Calculating the last year's worth of payments shows that HPGC Renmintongtai Pharmaceutical has a trailing yield of 2.5% on the current share price of CN¥5.68. If you buy this business for its dividend, you should have an idea of whether HPGC Renmintongtai Pharmaceutical's dividend is reliable and sustainable. So we need to check whether the dividend payments are covered, and if earnings are growing.
該公司的下一個股息支出是每股CN¥0.144。去年,該公司總計向股東派發CN¥0.14。計算去年的付款金額後發現,在當前每股CN¥5.68的股價上,HPGC人民同泰藥品的股息率爲2.5%。如果你想買入這個業務以獲得分紅,你需要了解HPGC人民同泰藥品的分紅是否可靠和可持續。所以我們需要檢查股息支出是否被覆蓋,以及收益是否增長。
Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. That's why it's good to see HPGC Renmintongtai Pharmaceutical paying out a modest 28% of its earnings. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. Over the past year it paid out 177% of its free cash flow as dividends, which is uncomfortably high. It's hard to consistently pay out more cash than you generate without either borrowing or using company cash, so we'd wonder how the company justifies this payout level.
股息通常是由公司收益支付的。如果公司支付的股息超過了利潤,那麼股息可能是不可持續的。這就是爲什麼看到HPGC人民同泰藥品支付了其收益的適度28%是好的。現金流比利潤對評估股息更爲重要,因此我們需要看到公司是否產生足夠的現金以支付其分配。在過去的一年中,它作爲股息支付了其自由現金流的177%,這是不舒服的。不借錢或使用公司現金而持續支付更多現金是很難的,所以我們想知道公司如何證明這個支付水平。
HPGC Renmintongtai Pharmaceutical paid out less in dividends than it reported in profits, but unfortunately it didn't generate enough cash to cover the dividend. Cash is king, as they say, and were HPGC Renmintongtai Pharmaceutical to repeatedly pay dividends that aren't well covered by cashflow, we would consider this a warning sign.
HPGC人民同泰藥品的股息支出比其利潤少,但不幸的是,它沒有產生足夠的現金來支付股息。正如他們所說的,現金是王中之王,如果HPGC人民同泰藥品一再支付沒有得到現金流充分覆蓋的股息,我們將認爲這是一個警告信號。
Click here to see how much of its profit HPGC Renmintongtai Pharmaceutical paid out over the last 12 months.
點擊此處查看HPGC人民同泰藥品在過去12個月中支付了多少利潤。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240722/0-530c43be8e5abde5b61cfb3d65e8cac5-0-58b36e58b27fbd88178582d50808cca1.png/big)
Have Earnings And Dividends Been Growing?
收益和股息一直在增長嗎?
Businesses with strong growth prospects usually make the best dividend payers, because it's easier to grow dividends when earnings per share are improving. If earnings fall far enough, the company could be forced to cut its dividend. With that in mind, we're encouraged by the steady growth at HPGC Renmintongtai Pharmaceutical, with earnings per share up 3.2% on average over the last five years. Earnings have been growing somewhat, but we're concerned dividend payments consumed most of the company's cash flow over the past year.
業務增長前景強勁的公司通常是最好的分紅派息者,因爲在每股收益改善時增加分紅較容易。如果收益下降得足夠多,公司可能被迫削減其股息。考慮到這一點,我們對HPGC Renmintongtai Pharmaceutical穩定的增長感到鼓舞,過去五年平均每股收益增長了3.2%。收益有所增長,但我們擔憂去年股息支付消耗了公司大部分現金流。
Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. HPGC Renmintongtai Pharmaceutical has delivered 0.8% dividend growth per year on average over the past 10 years.
許多投資者將評估公司的股息表現,通過評估股息支付在一段時間內的變化情況。HPGC Renmintongtai Pharmaceutical過去10年平均每年提供0.8%的股息增長。
The Bottom Line
還有一件事需要注意的是,我們已經確定了上海醫藥的2個警告信號,了解這些信號應該成爲你的投資過程的一部分。
Has HPGC Renmintongtai Pharmaceutical got what it takes to maintain its dividend payments? HPGC Renmintongtai Pharmaceutical has seen its earnings per share grow steadily and paid out less than half its profit over the last year. Unfortunately, its dividend was not well covered by free cash flow. Overall we're not hugely bearish on the stock, but there are likely better dividend investments out there.
HPGC人民同泰藥品的股息支出是否具備維持其股息支付所需的條件? HPGC人民同泰藥品的每股收益穩步增長,過去一年中的股息支出也不到其利潤的一半。但不幸的是,其股息不被自由現金流充分覆蓋。總的來說,我們並不是非常看淡這隻股票,但可能有更好的股息投資。
If you want to look further into HPGC Renmintongtai Pharmaceutical, it's worth knowing the risks this business faces. For example - HPGC Renmintongtai Pharmaceutical has 1 warning sign we think you should be aware of.
如果您想進一步了解HPGC人民同泰藥品,了解此業務面臨的風險是值得的。例如- HPGC人民同泰藥品有一個我們認爲你應該知道的警告信號。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
一般來說,我們不建議僅僅購買第一個股息股票。下面是一個經過策劃的有趣的、股息表現良好的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。